drugset / Trial / NCT07523711
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
Timeline
- Start
- 2026-04-09
- Primary completion
- 2026-11-18
- Completion
- 2026-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maridebart Cafraglutide | Unknown | — | Subcutaneous |
| Subject | Norgestimate | Small molecule | — | Oral |
| Subject | ethinyl estradiol | Small molecule | — | Oral |